Background: Extensive ‘cauliflower-like’ condyloma acuminatum (CA) in males is commonly treated with CO2 laser surgery or with electrosurgery. Studies on the long-term outcome in this specific situation are scarce. Objectives: To determine the cure and recurrence rate in relation to the HIV status and endoanal location of lesions. To determine the complication rate and patient satisfaction. Methods: Questionnaire-based retrospective long-term study on 64 consecutive men (answer rate 60% or 64/107 addressed persons). The mean follow-up was 25 months (range 7–75). Results: The overall cure rate after 1 intervention was 67%. The cure rate in HIV-positive versus HIV-negative patients was 58 versus 71% (odds ratio = 1.79; p = 0.38). Endoanal versus perianal location was associated with a cure rate of 56 versus 84% (odds ratio = 4.06; p = 0.03). After a second treatment session, the cure rate increased to 79% or higher in all subgroups. Painful defecation for an average of 4–5 weeks was the main postoperative complaint. Severe complications were not seen or reported. Conclusions: The CO2 laser is a valuable and safe treatment to debulk extensive ‘cauliflower- like’ anogenital CA in males. The healing rate in HIV-positive patients is not significantly lower than in HIV-negative patients. Endoanal location of lesions is a risk factor for recurrence.

Keywords:
Condyloma acuminatum, Human papillomavirus, Men, CO2 laser, Endoanal condyloma, Cauliflower-like condyloma, Recurrence
1.
Koutsky L: Epidemiology of genital human papillomavirus infection. Am J Med 1997;1997(suppl 5A):3–8.
2.
Munk C, Svare EL, Poll P, Bock JE, Kjaer SK: History of genital warts in 10,838 women 20 to 29 years of age from the general population. Sex Transm Dis 1997;24:567–572.
3.
Severson J, Evans TY, Lee P, Chan TS, Arany I, Tyring SK: Human papillomavirus infections: Epidemiology, pathogenesis, and therapy. J Cutan Med Surg 2001;5:43–60.
4.
Gross G: Klinik und Therapie anogenitaler Warzen und papillomvirusassoziierter Krankheitsbilder. Hautarzt 2001;52:6–17.
5.
Rüdlinger R, Grob R, Buchmann P, Christen D, Steiner R: Anogenital warts of the condyloma acuminatum type in HIV-positive patients. Dermatologica 1988;176:277–281.
6.
Beutner KR, Ferenczy A: Therapeutic approaches to genital warts. Am J Med 1997;102(suppl 5A):28–37.
7.
Beutner KR, Wiley DJ, Douglas JM, Tyring SK, Fife K, Troffatter K, Stone KM: Genital warts and their treatment. Clin Infect Dis 2001;28(suppl 1):S37–56.
8.
Tyring S, Edwards L, Cherry LK, Ramsdell WM, Kotner S, Greenberg MD, Vance JC, Barnum G, Dromgoole SH, Killey FP, Toter T: Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Arch Dermatol 1998;134:33–38.
9.
White DJ, Billingham C, Chapman S, Drake S, Jayaweera D, Jones S, Opaneye A, Temple C: Podophyllin 0.5% or 2.0% vs podophyllotoxin 0.5% for the self-treatment of penile warts: A double blind randomised study. Genitourin Med 1997;73:184–187.
10.
Syed TA, Lundin S: Topical treatment of penile condylomata acuminata with podophyllotoxin 0.3% solution, 0.3% cream and 0.15% cream. Dermatology 1993;187:30–33.
11.
Abdullah AN, Walzman M, Wade A: Treatment of external genital warts comparing cryotherapy (liquid nitrogen) and trichloroacetic acid. Sex Transm Dis 1993;20:344–345.
12.
Swinehart JM, Sperling M, Phillips S: Intralesional fluorouracil/epinephrine injectable gel for treatment of condylomata acuminata. Arch Dermatol 1997;133:67–73.
13.
Edwards L, Ferenczy A, Eron L, Baker D, Owens ML, Fox TL, Hougham AJ, Schmitt KA (HPV Study Group): Self-administered topical 5% imiquimod cream for external anogenital warts. Arch Dermatol 1998;134:25–30.
14.
Fife KH, Ferenczy A, Douglas JM, Brown DR, Smith M, Owens ML: Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily or three times a day. Sex Transm Dis 2001;28:226–231.
15.
Garland SM, Sellors JW, Wikstrom A, Petersen CS, Aranda C, Aractingi S, Maw RD (Imiquimod Study Group): Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts – Results of an open-label, multicenter phase IIIb trial. Int J STD AIDS 2001;12:722–729.
16.
Armstrong DKB, Maw RD, Dinsmore WW, Blaakaer J, Correa MAG, Falk L, Ferenczy AS, Fortier M, Frazer I, Law C, Moller BM, Oyakawa N: Combined therapy trial with interferon alpha 2a and ablative therapy in the treatment of anogenital warts. Genitourin Med 1996;72:103–107.
17.
The Condyloma International Collaborative Study Group: Randomized placebo-controlled double-blind combined therapy with laser surgery and systemic interferon alpha 2a in the treatment of anogenital condylomata acuminata. J Infect Dis 1993;167:824–829.
18.
Christen D, Buchmann P, Grob P, Simmen HP: Anal condylomata acuminata in HIV positive patients. Langenbecks Arch Chir 1992;377:207–210.
19.
Ferenczy A, Behelak Y, Haber G, Wright TC, Richart RM: Treating vaginal and external anogenital condylomas with electrosurgery vs CO2 laser ablation. J Gynecol Surg 1995;11:41–50.
20.
Fierlbeck G, Schiebel U, Müller C: Immunohistology of genital warts in different stages of regression after therapy with interferon gamma. Dermatologica 1989;179:191–195.
21.
Syed TA, Cheema KM, Khayyami M, Ahmad SH, Ahmad S, Ahmad SA: Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males. Dermatology 1995;191:129–132.
22.
Gross G, Roussaki A, Baur S, Wiegand M, Mescheder A: Systemically administered interferon alfa-2a prevents recurrence of condylomata acuminata following CO2 laser ablation: The influence of the cyclic low-dose therapy regimen. Results of a multicenter double-blind placebo-controlled clinical trial. Genitourin Med 1996;72:71.
23.
Gross G, Rogozinski T, Schöfer H, Jablonska S, Roussaki A, Wöhr C, Brzonska J: Recombinant interferon beta gel as an adjuvant in the treatment of recurrent genital warts: Results of a placebo-controlled double-blind study in 120 patients. Dermatology 1998;196:330–334.
24.
van Krogh G, Wikström A, Syriänan K, Syriänan S: Anal and penile condylomas in HIV-negative and HIV-positive men: Clinical, histological and virological characteristics correlated to therapeutic outcome. Acta Derm Venereol (Stockh) 1995;75:470–474.
25.
Tschanz C, Salomon D, Skaria A, Masouyé I, Vecchietti GL, Harms M: Vulvodynia after CO2 laser treatment of the female genital mucosa. Dermatology 2001;202:371–372.
26.
Alam M, Stiller M: Direct medical costs for surgical and medical treatment of condylomata acuminata. Arch Dermatol 2001;137:337–341.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.